Objective-Proliferation of vascular smooth muscle cells (VSMCs) is a crucial event in the pathogenesis of intimal hyperplasia, the main cause of restenosis following vascular reconstruction. Here, the impact of sonic hedgehog (Shh)/Gli family zinc finger 2 (Gli2) signaling on VSMC proliferation was assessed. Methods and Results-Increased Shh signaling was detected in VSMCs in the neointima of vein grafts obtained from mice undergoing restenosis. Comparable results were found in primary cultured human VSMCs (hVSMCs) obtained from patients undergoing coronary bypass surgery, which were used to further assess the impacts of Shh signaling on VSMC proliferation. Inhibition of Shh signaling in hVSMCs through treatment with cyclopamine or knockdown of Gli2 results in G 1 arrest and reduced cyclin D1, cyclin E, and phosphorylated retinoblastoma (pRB) levels. In contrast, activation of Shh/Gli2 signaling in hVSMCs results in increased levels of G 1 cyclins and promotes G 1 -S transition. Stimulation of hVSMC proliferation by Shh is abolished by cyclin D1 knockdown. Conclusion-Combined, these results demonstrate that Shh/Gli2 signaling stimulates VSMC proliferation via regulation of the G 1 cyclin-retinoblastoma axis and suggest that antagonists that target the Shh pathway may be therapeutically beneficial in the prevention of intimal hyperplasia. (Arterioscler Thromb Vasc Biol. 2010;30:1787-1794.)
V ascular smooth muscle cell (VSMC) proliferation is a key event in the pathogenesis of vascular diseases and is characterized by intimal thickening most commonly seen in atherosclerosis, vascular rejection, restenosis after vein grafting, and coronary intervention. [1] [2] [3] [4] Various growth factors, including platelet-derived growth factor (PDGF), basic fibroblast growth factor, and insulin-like growth factor, stimulate cell proliferation via different signaling mechanisms, which converge at cyclins/cyclin-dependent kinases and cyclindependent kinase inhibitors, common regulators of the cell cycle. [5] [6] [7] [8] Growth factor-mediated activation of cyclins D1 and E and their corresponding cyclin-dependent kinases leads to hyperphosphorylation of the retinoblastoma (Rb) protein, 9 which results in release of E2F and transcriptional activation of genes required to facilitate G 1 -S transition. 10 We previously uncovered genetic interactions between components of the Rb/E2F and hedgehog (Hh) (the fly homologue of the mammalian sonic Hh [Shh] ) pathways that are critical for G 1 -S transition during development. 11 The Shh/Gli2 signaling pathway controls pattern formation, cellular proliferation, and differentiation of a number of different cell types during vertebrate embryogenesis. 12, 13 In the absence of Shh ligand, the transmembrane receptor Patched1 (Ptch1) functions to repress the pathway by binding to and inhibiting the transmembrane protein Smoothened (Smo) . Binding of Shh to Ptch1 results in release of Smo 14, 15 and activation of Gli1 and/or Gli2, members of the Gli family of zinc finger transcription factors, which induce transcription of Shh-target genes. 16 -20 Aberrant Shh/Gli2 signaling has been shown to play a role in the development of a number of different types of malignancies, including medulloblastoma, rhabdomyosarcoma, and basal cell carcinoma. 20 -23 In some common, highly aggressive cancers of the lung, gastrointestinal tract, and pancreas, Shh signaling acts via induction of cyclin D1 and other Rb signaling proteins to promote survival of residual transformed cells, suggesting that Shh signaling is involved in both tumor formation as well as tumor maintenance. 24 -26 Given that Shh can stimulate cell proliferation during development and cancer, it was hypothesized that Shh might function to induce VSMC proliferation. The results of this study indicate that Shh/Gli2 signaling induces VSMC proliferation via the Rb/E2F pathway, suggesting that Shh plays a key role in intimal hyperplasia.
Materials and Methods
Reagents C57/B6 mice were purchased from the Experimental Animal Center of China Medical University. Cyclopamine, propidium iodide, and Hoechst 33258 were obtained from Sigma-Aldrich. Recombinant Shh protein and PDGF-BB were purchased from Peprotech. Antibodies raised against the following proteins were used in this investigation: Ptch1 (Santa Cruz Biotechnology, Inc.), Shh (Genetex), Gli2 (Lifespan), Ki67 (Abcam), cyclin D1, cyclin E, and Ser795-Rb (phosphorylated retinoblastoma [pRb]; Cell Signaling). 5-Bromodeoxyuridine (BrdUrd) incorporation was assayed through a kit purchased from Roche Applied Science.
Cell Culture
Human saphenous veins were obtained from patients undergoing coronary artery bypass surgery. Primary human VSMCs (hVSMCs) were grown from human saphenous vein segments and cultured in collagen-coated culture dishes as previously reported. 27 Briefly, vein segments were dissected to remove the adventitia, and the endothelium was scraped away. The vein segments were cut into 0.7-mm squares and placed in 45-cm 2 tissue culture flasks. Over a period of 2 to 5 weeks, VSMCs proliferated to form a confluent layer. Cells were passed 3 to 6 times. Cells were grown in DMEM (high glucose; Hyclone) supplemented with 10% fetal bovine serum at 37°C in the presence of 5% CO 2 .
Lentivirus-and Retrovirus-Mediated Delivery of Small Interfering RNA (siRNA)
The pLVTHM-Gli2 siRNA vector was kindly provided by Vladimir S. Spiegelman (University of Wisconsin School of Medicine and Public Health, Madison) and used as described previously. 28 pEGFPN1-Cyclin D1 siRNA was designed as follows: an artificially synthesized Cyclin D1 siRNA, which was previously shown to efficiently knock down cyclin D1 expression, was ligated into a NotI-XbaI-digested plasmid pEGFPN1 29 
Transfection and Construction of Stable Cell Lines
The Gli2 cDNA expression plasmid pcDNA3.1-Flag-Gli2 was obtained as a gift from M. Grachtchouk and A. Dlugosz (University of Michigan, Ann Arbor). Transfections were carried out using Lipofectamine Plus reagents according to the manufacturer's instructions (Invitrogen). For stable transfections, cells were plated at a density of 5ϫ10 5 per 60-mm tissue culture dish 18 to 24 hours before transfection. Cells were transfected with either Gli2-pcDNA or pcDNA (empty vector). After 48 hours, cells were plated at a low density in selection medium containing 800 g/mL geneticin (G418). Once colonies were formed, individual colonies were isolated and expanded. Cells were continuously maintained in medium containing 800 g/mL G418.
Proliferation Assays
VSMCs were plated in 24-well plates and grown to 70% confluence. Cells were serum starved for 24 hours and stimulated with PDGF for 48 hours, then cell proliferation was assessed by cell counting, BrdUrd assays, and Ki-67 immunofluorescent staining. Cells were counted by a hemocytometer. BrdUrd incorporation assays were performed according to the manufacturer's (Roche) instructions. For Ki-67 immunofluorescent staining, PDGF-stimulated cells were fixed with methanol at Ϫ20°C for 2 minutes and stained with anti-Ki-67 primary antibody (1:100, rabbit antihuman) according to the staining procedure described below. Cells were examined and images recorded using a fluorescence microscope (BX61/DP71; Olympus).
Western Blot Analysis
Semiquantitative analysis of proteins in cell lysates was performed by Western blotting and antibody detection as previously described. 30 Briefly, VSMCs were grown on 6-well culture dishes to 70% confluence. Cells were serum starved for 24 hours and stimulated with or without growth factor for 48 hours. Cells were then harvested in lysis buffer. Following a 15-minute incubation on ice, lysates were centrifuged at 12 000 g for 20 minutes, and protein content was determined in supernatants using Protein DC Assays in conjunction with a UV-VIS spectrophotometer (UV3103PYE; UNI-CAM). Protein lysates (40 g of each sample) were resolved on 10% sodium dodecyl sulfate-polyacrylamide gels and transferred to PVDF membranes. Membranes were blocked for 1 hour with 5% nonfat dry milk in PBS at room temperature and then incubated overnight in primary antibodies (1:2000) at 4°C. After extensive washing, membranes were incubated in secondary antibodies (1:1000) at room temperature, and proteins were visualized using the enhanced chemiluminescence plus system (Pierce) according to the manufacturer's instructions.
Flow Cytometric Cell Cycle Analysis
Cells were treated as indicated and trypsinized. After overnight fixing in 75% methanol at Ϫ20°C, cells were washed in PBS and incubated with 100 ng/mL ribonuclease (Roche Diagnostics) and 10 ng/mL propidium iodide in PBS for 1 hour at 37°C. Samples were analyzed for DNA content using a cell sorter (FACSCalibur). Data were analyzed using ModFit LT 3.0 software.
Vein Graft Procedure
Mouse vein grafts were prepared as previously described. 31 In brief, 60 C57/B6 mice were anesthetized using 10% chloral hydrate. The left external jugular vein was grafted onto the infrarenal abdominal aorta using an 11/0 Ethilon suture (Ethicon, Inc.) in a nonreversed configuration. Between 6 and 7 interrupted sutures were required per end. The infrarenal abdominal aorta was clamped for an average of 68 minutes. The operative field was irrigated thoroughly with penicillin saline before closing the muscle and skin. Vein grafts and contralateral control veins were harvested 2 weeks after grafting.
Immunofluorescence Staining
Immunofluorescence was performed on VSMCs seeded at a density of 10 4 /well in a 24-well chamber slide. After the indicated treatments, cells were washed with PBS and fixed in ice-cold methanol. Slides were blocked with 5% BSA and then incubated with primary and secondary fluorescein isothiocyanate-labeled or rhodaminelabeled antibodies. Nuclei were visualized by Hoechst 33258 staining, and images were recorded using laser confocal microscopy (FV1000S-SIM/IX81; Olympus).
Immunofluorescent staining of vein grafts was preformed as described previously. 32 Briefly, 5-m serial, frozen sections were incubated with a primary antibody overnight and a secondary antibody conjugated with fluorescein isothiocyanate or rhodamine. Nuclei were stained with Hoechst 33258.
Statistical Analyses
Data are presented as meanϮSEM. All data were analyzed using SPSS version 13.0 (SPSS, Inc.). A probability value of Ͻ0.05 was considered statistically significant.
Results

Shh/Gli2 Signaling in Vein Grafts
Immunohistochemistry was used to examine levels of Shh, Ptc1, and Gli2 in vein grafts obtained from mice undergoing restenosis for 2 weeks. A significantly higher number of VSMCs express Shh/Gli2 signaling proteins in these vein grafts when compared with control contralateral veins, suggesting that Shh/Gli2 signaling is activated during restenosis ( Figure 1A through 1C ). In contrast, there is little Desert hedgehog, Indian hedgehog, and Gli1 expression both in control and vein grafts and no indication that these proteins are induced during restenosis (supplemental Figure I , available online at http://atvb.ahajournals.org). Shh/Gli2 signaling in vein grafts coincides with increased proliferating cell nuclear antigen levels ( Figure 1D ). Taken together, these observations suggested that Shh/Gli2 may promote VSMC proliferation in arterializing vein grafts.
Shh/Gli2 Signaling in hVSMCs
PDGF, which is expressed at high levels in vein grafts, is known to stimulate VSMC proliferation and intimal hyperplasia. 32 To examine whether Shh/Gli2 signaling is activated during VSMC proliferation, quiescent hVSMCs obtained from coronary bypass patients and grown in primary culture were treated with PDGF, and the levels of Shh, Ptc1, and Gli2 were examined. PDGF treatment of hVSMCs resulted in cell proliferation (data not shown), as well as upregulated levels of Shh, Ptc1, and Gli2, which were induced beginning at 8 hours, and lasting through 48 hours (see Figure 2A through 2C and supplemental Figure II ).
Shh/Gli2 Signaling Promotes VSMC Proliferation
The effects of modulating Shh/Gli2 signaling on hVSMC proliferation were assessed 48 hours after growth factor stimulation ( Figure 3A and 4A) , when the levels of Shh signaling proteins are very high (supplemental Figure II) . Either the Smo inhibitor cyclopamine or lentivirus-Gli2 siRNA were used to inhibit the Shh signaling pathway. Both approaches resulted in suppression of hVSMC numbers by 50 and 54% 48 hours after PDGF treatment, respectively. Br-dUrd incorporation assays confirmed these results, indicating that DNA replication was downregulated by 53 and 56%, respectively, in these 2 groups of cells (nϭ4; Figure 3B and 3C). Ki-67 expression, a marker for proliferating cells, was also assessed. The number of Ki-67-positive cells was reduced following treatment with cyclopamine or knockdown of Gli2 ( Figure 3D) .
In contrast, cells treated with recombinant N-Shh or Gli2 cDNA exhibited an upregulation in cell proliferation by 60 and 67%, respectively, 48 hours after growth factor stimulation. BrdUrd incorporation assays confirmed these results and showed that treatment with Shh or overexpression of Gli2 resulted in an increase in cell proliferation by 42 and 39%, respectively (nϭ4; Figure 4B and 4C). Transfection with Gli2 cDNA or treatment with recombi- Figure 1 . Shh signaling is activated in smooth muscle cells in grafts undergoing restenosis. Tissues were harvested from grafts and contralateral normal parts (control) 2 weeks postoperatively. Serial sections were stained (red) for (A) Shh, (B) Ptch1, and (C) Gli2. All sections were also stained for ␣-actin (green; A through C) and DNA (blue, A through C). D, Protein lysates were subjected to immunoblotting for Shh, Ptch1, Gli2, and proliferating cell nuclear antigen (PCNA). ␤-Actin serves as an internal control. Each lane represents protein from a single vessel obtained in a representative experiment.
nant Shh also resulted in a greater percentage of Ki-67positive cells ( Figure 4D ). It should be noted that treatment of cells with Shh or Gli2-cDNA in the absence of PDGF stimulation resulted in a comparable increase in the number of Ki67-positive cells ( Figure 4E ). Together, these data support the conclusion that Shh/Gli2 promotes mitogenic activity in hVSMCs.
Shh/Gli2 Promotes G 1 -S Transition in hVSMCs
Fluorescence-activated cell sorting was used to study the impacts of Shh/Gli2 signaling on cell cycle phasing. These analyses demonstrated that inhibition of Shh/Gli2 signaling prevents G 1 -S transition 48 hours after PDGF stimulation (see Figure 5A and supplemental Figure IIIA) . These results were supported by analysis of the levels of cell cycle proteins.
PDGF treatment resulted in upregulated levels of cyclin D1, cyclin E, and pRb ( Figure 5B ). These effects were blocked by treatment with cyclopamine or Gli2 siRNA ( Figure 5B ). It should be noted that treatment with Shh or Gli2-cDNA in the absence of PDGF stimulation induces G 1 -S transition ( Figure  5C ) and the G 1 cyclin-Rb axis ( Figure 5D ).
The requirement of cyclin D1 in Shh-induced VSMC proliferation was assessed. Shh failed to induce cell proliferation in cells in which cyclin D1 was knocked down through retroviral siRNA delivery ( Figure 6) , as assessed by cell counts (Figure 6B ), BrdUrd incorporation assays ( Figure 6C Blocking endogenous Shh signaling inhibits hVSMC proliferation. hVSMCs were treated with cyclopamine (5 mol/L) or infected with a lentiviral vector carrying scrambled siRNA (control) or Gli2 siRNA sequences. A, Gli2 knockdown was confirmed by Western blot analyses. B through D, Cells were stimulated with PDGF for 48 hours, and cell proliferation was assessed by cell counts (B), BrdUrd incorporation (C), and immunofluorescence staining for Ki-67 expression (red; D). These assays indicate that Shh signaling is required for induction of hVSMC proliferation following growth factor stimulation. An asterisk indicates a statistically significant difference (PϽ0.05) compared with controls.
Discussion
The pathogenesis of vascular-related disorders, such as postangioplasty restenosis, bypass vein graft failure, and cardiac allograft vasculopathy, is dictated, among other factors, by aberrant proliferation of VSMCs. [33] [34] [35] We previously showed that the G 1 -S transition of the cell cycle is regulated by the Shh/Gli2 signaling pathway. 11 The results of the present investigation demonstrate that Shh signaling is activated following vein grafting in mice (Figure 1) . PDGF, which is expressed at high levels in vein grafts, is known to stimulate VSMC proliferation and intimal hyperplasia. 32 PDGF stimulation of hVSMCs results in induction of Shh signaling (Figure 2 ), which promotes cell proliferation (Figure 3 ). This induction of cell proliferation is accomplished by upregulation of the levels of cyclin D1 and cyclin E ( Figure 5 ), which promote phosphorylation of Rb 36 and G 1 -S transition of hVSMCs (Figure 4 ). This stimulation of cell proliferation by regulation of the G 1 cyclin-Rb axis is inhibited when Shh signaling is blocked (Figures 3 and 5) , indicating that growth factor stimulates hVSMC proliferation via induction of Shh signaling. The results of this analysis do not exclude the possibility that PDGF induces proliferation independently of Shh signaling, but this investigation has focused on analysis of Shh-induced VSMC proliferation.
Shh signaling does not induce proliferation when cyclin D1 is knocked down (Figure 6 ), suggesting that induction of this G 1 cyclin is required for Shh to induce VSMC cell proliferation. Cyclin D1 is a known transcriptional target of Gli2, 37 and stimulation of cyclin D1 levels by Shh signaling ( Figure  5 ) likely occurs directly through regulation of Cyclin D1 transcription by Gli2 in hVSMCs. Our previous work demonstrated that Cyclin E is a transcriptional target of Hh signaling, 11 suggesting that the upregulation of cyclin E by Shh, which is observed in VSMCs ( Figure 5 ), is likely direct.
Together, these data, suggest that VSMC proliferation during restenosis following vascular surgery is regulated by Shh/ Gli2 signaling, which induces cell proliferation via the G 1 cyclin-Rb axis.
Shh is an angiogenic agent that regulates both normal and aberrant blood vessel formation. During development, Shh drives development of pulmonary capillary networks and stimulates assembly and remodeling of branchial arch blood vessels. 38 -41 Shh signaling has also been linked to tumor angiogenesis in a variety of cancers. [42] [43] [44] The source of Shh-positive cells in vessel walls has been a question of interest. Recently, Passman et al 45 found that the local presence of Shh in the adventitial layer of the mouse artery wall may attribute to the maintenance of smooth muscle progenitor cells. However, as Passman et al 45 reported, only a little amount of Shh can be seen in vein adventitia of a P2 adult mouse, and in our article, we found high expression of Shh in the neointima of vein grafts (Figure 1 ). We thus propose that physiologically differential expression of Shh between artery and vein may exist at adult stages, whereas during vein damage, extra stress and local inflammatory factors may directly upregulate Shh in injured intima. Alternatively, previous studies on restenosis and neointimal hyperplasia suggested that stem cells of bone marrow origin are the proliferative cells driving neointima formation. 46, 47 We therefore infer that Shh-positive cells in vein grafts may be derived from marrow. In addition, both endogenous and dedifferentiation-derived smooth muscle stem cells may evolve into Shh-positive propagating cells. 48 We hope to explore these possibilities in our future research.
The impacts of Shh signaling on VSMC described here are in agreement with investigations conducted by Morrow et al, 49, 50 who reported that Shh facilitates the proliferation of SMC in vitro. In the current investigation, we elucidate the molecular pathway involved in this process by linking Shh/ Gli2 induction of VSMC proliferation to the cyclinD1/Rb/ E2F pathway. Moreover, in this investigation, Shh signaling is linked to a mouse model for graft restenosis, a clinical hot spot. These findings may provide important insights into the pathogenesis and treatment of vascular diseases, such as atherosclerosis and intimal hyperplasia after vein grafting, and suggest that inhibition of Shh signaling might prove to be therapeutically useful in the prevention of intimal hyperplasia.
A number of antagonists targeting the Shh pathway have been identified in recent years. Cyclopamine and the majority of these antagonists target Smo. Two small molecule Smo antagonists, GDC-0449 and IPI-926, have entered clinical trials for treatment of basal cell carcinoma and pancreatic cancer. 51, 52 Furthermore, recent studies have suggested that a cyclopamine-lovastatin combinatorial treatment may be useful for treating medulloblastomas. 53 This combinatorial approach is an interesting prospect given that cardiac patients who might benefit from the administration of Smo antagonists to prevent intimal hyperplasia would in many cases already be taking statins to lower their cholesterol levels. 
